Omeprazole: Mechanism, Pharmacokinetics, and Drug Interactions
Mechanism of Action
Omeprazole is a proton pump inhibitor that irreversibly blocks the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, representing the final common pathway of acid secretion regardless of the stimulus. 1 The drug is a weak base that becomes activated in the acidic environment of active parietal cells, where it undergoes acid-catalyzed conversion to its active sulfenamide form 2. This mechanism explains why the antisecretory effect (lasting up to 72 hours) far exceeds the plasma half-life, as the drug remains bound to the enzyme even after being cleared from plasma 1.
Plasma Half-Life
The plasma elimination half-life of omeprazole is less than 1 hour (0.5-1 hour), with the drug being almost entirely cleared from plasma within 3-4 hours. 1, 3 Peak plasma concentrations occur within 0.5 to 3.5 hours after oral administration of delayed-release formulations 1. In elderly patients, the half-life approximately doubles to about 1 hour, with plasma clearance reduced to 250 mL/min compared to 500-600 mL/min in younger patients 1. In patients with severe hepatic impairment (Child-Pugh Class C), the half-life extends to nearly 3 hours 1.
Interactions with P-glycoprotein
Omeprazole is both a substrate and inhibitor of P-glycoprotein, though the clinical significance appears limited. 4 In vitro studies using Caco-2 and L-MDR1 cells demonstrated that omeprazole exhibits polarized transport with greater basal-to-apical than apical-to-basal movement at 5 μM concentrations 4. However, the P-glycoprotein inhibitor PSC-833 showed minimal effect on omeprazole transport, suggesting other transporters contribute significantly to its cellular translocation 4. As an inhibitor, omeprazole blocks P-glycoprotein-mediated digoxin transport with an IC50 of 17.7 μM 4.
Interactions with CYP2D6
Omeprazole does not significantly interact with CYP2D6. 5 In vitro studies demonstrate that omeprazole is a poor inhibitor of CYP2D6-mediated bufuralol 1'-hydroxylation, with IC50 values exceeding 200 μM 5. This lack of interaction is clinically relevant, as it distinguishes omeprazole from drugs like cimetidine, which inhibits multiple CYP enzymes including CYP2D6 6.
Key CYP Interactions to Note:
- CYP2C19: Omeprazole is primarily metabolized by CYP2C19 and acts as a time-dependent inhibitor of this enzyme, with competitive inhibition Ki values of 2-6 μM 1, 5. This creates autoinhibition and nonlinear pharmacokinetics with repeated dosing 1.
- CYP3A4: Secondary metabolic pathway; omeprazole is a weak inhibitor 1, 5
- CYP2C9: Minimal inhibitory effect compared to other PPIs 5
Effect on QT Interval
Omeprazole can cause mild QT interval prolongation, though the clinical significance in most patients appears modest. Recent evidence shows variable effects:
- In a 2023 animal study using halothane-anesthetized dogs, omeprazole tended to prolong the QT interval and QTcV, and shortened the terminal repolarization period at high doses 7
- A 2024 retrospective analysis of 24,512 ICU patients found that PPI use (predominantly omeprazole) was associated with increased risk of QT prolongation (OR 1.66 vs H2RAs, OR 1.54 vs no acid suppression) 8
- Importantly, omeprazole showed lower risk compared to pantoprazole (OR 2.14) and lansoprazole (OR 1.80) in the same study 8
Clinical Caveat:
The QT prolongation risk is amplified when omeprazole is combined with other QT-prolonging medications 8. Patients with reduced ventricular repolarization reserve require particular caution 7.
Effect on Cardiac Conduction
Omeprazole prolongs the QRS width, indicating effects on ventricular depolarization and conduction. 7 At high doses (5 mg/kg in animal models), omeprazole also prolonged the ventricular effective refractory period 7. The drug exhibits dose-dependent hemodynamic effects: low-to-middle doses increase heart rate and cardiac output while decreasing peripheral vascular resistance, but high doses plateau or reverse these effects 7.
Important Clinical Considerations:
- Plasma half-life of less than 2 hours suggests that timing of administration may minimize drug interactions, though definitive evidence for this strategy is lacking 6
- Volume of distribution is 0.3 L/kg, corresponding to extracellular water 3
- Protein binding is approximately 95% 1
- Bioavailability increases from 35% after single dose to 60% with repeated dosing due to reduced first-pass metabolism from CYP2C19 autoinhibition 3